Ophthalmology Times posts ocular toxicity scales

Ophthalmology Times highlighted a December 2025 JAMA Ophthalmology consensus report that replaces the old catch-all way of grading cancer-drug eye side effects with six separate scales built for real treatment decisions. (ophthalmologytimes.com) The practical change is the structure. Instead of forcing ophthalmologists and oncologists to work from ocular CTCAE categories that the study authors said mixed signs and symptoms and lacked standardized photos or dose-modification guidance, the new framework breaks events into six areas: visual acuity, eye symptoms, cornea, conjunctiva/sclera, anterior chamber, and retina/posterior segment. (ophthalmologytimes.com) That matters because the question in clinic is often not just “How bad is this?” but “Can the drug continue, should the dose change, or does treatment need to pause?” The consensus report was designed specifically to make those calls clearer for experimental oncology drugs, especially antibody-drug conjugates. (ophthalmologytimes.com) A big driver is corneal toxicity from antibody-drug conjugates. Ophthalmology Times said corneal pseudomicrocysts can occur in up to 90% of patients on some ADC therapies, which makes consistent grading more than a documentation issue. (ophthalmologytimes.com) The panel behind the report was multidisciplinary. JAMA Ophthalmology said the consensus process included ophthalmologists, oncologists and U.S. Food and Drug Administration personnel, and the lead author was Neel D. Pasricha of the University of California, San Francisco and the Francis I. Proctor Foundation. (ophthalmologytimes.com) Their critique of the prior system was direct: ambiguous scales were producing unreliable grading and unclear recommendations for experimental oncology drug dose changes. The replacement is meant to standardize how findings are described and communicated across specialties. (jamanetwork.com) The timing also reflects how crowded this drug category has become. Ophthalmology Times said the panel pointed to 12 FDA-approved ADCs and more than 160 in clinical trials, raising the odds that ophthalmologists will keep seeing treatment-related eye findings in cancer patients. (ophthalmologytimes.com) The broader thread here is coordination. The report and follow-on coverage frame these scales as a way to make ophthalmology exams more actionable for oncology teams, with more objective incidence measurement, representative photographs and more reproducible reporting in trials and practice. (ophthalmologytimes.com) If this framework sticks, the immediate effect is likely to be less back-and-forth over vague labels and more reports that connect a specific ocular finding to a specific treatment decision. That is an inference from the authors’ stated goal of clearer dose-modification recommendations and more reliable grading. (ophthalmologytimes.com)